- Home
- HGTY vs AVXL Comparison
HGTY vs AVXL Comparison
Compare HGTY & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- AVXL
- Stock Information
- Founded
- HGTY 1984
- AVXL 2004
- Country
- HGTY United States
- AVXL United States
- Employees
- HGTY N/A
- AVXL N/A
- Industry
- HGTY Specialty Insurers
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HGTY Finance
- AVXL Health Care
- Exchange
- HGTY Nasdaq
- AVXL Nasdaq
- Market Cap
- HGTY 1.1B
- AVXL 956.7M
- IPO Year
- HGTY N/A
- AVXL N/A
- Fundamental
- Price
- HGTY $11.11
- AVXL $8.62
- Analyst Decision
- HGTY Hold
- AVXL Strong Buy
- Analyst Count
- HGTY 7
- AVXL 3
- Target Price
- HGTY $13.67
- AVXL $44.00
- AVG Volume (30 Days)
- HGTY 109.6K
- AVXL 1.4M
- Earning Date
- HGTY 11-04-2025
- AVXL 08-12-2025
- Dividend Yield
- HGTY N/A
- AVXL N/A
- EPS Growth
- HGTY 90.09
- AVXL N/A
- EPS
- HGTY 0.20
- AVXL N/A
- Revenue
- HGTY $1,303,397,000.00
- AVXL N/A
- Revenue This Year
- HGTY $15.91
- AVXL N/A
- Revenue Next Year
- HGTY N/A
- AVXL N/A
- P/E Ratio
- HGTY $54.43
- AVXL N/A
- Revenue Growth
- HGTY 17.90
- AVXL N/A
- 52 Week Low
- HGTY $8.03
- AVXL $5.22
- 52 Week High
- HGTY $13.32
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- HGTY 37.09
- AVXL 41.72
- Support Level
- HGTY $11.04
- AVXL $8.41
- Resistance Level
- HGTY $11.35
- AVXL $9.50
- Average True Range (ATR)
- HGTY 0.36
- AVXL 0.53
- MACD
- HGTY -0.11
- AVXL -0.03
- Stochastic Oscillator
- HGTY 3.46
- AVXL 25.25
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.